Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term EC 2-7-1 (mTOR protein). Found 3 abstracts

Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global AT. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. New England Journal of Medicine. 2007 May 31;356(22):2271-81.
Robb VA, Astrinidis A, Henske EP. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.[erratum appears in Mod Pathol. 2006 Jun;19(6):889]. Modern Pathology. 2006 Jun;19(6):839-46.
Altomare DA, Wang HQ, Skele KL, De Rienzo A, Klein-Szanto AJ, Godwin AK, Testa JR. AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene. 2004 Jul 29;23(34):5853-7.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term EC 2-7-1 (mTOR protein)

pa [Pathology] EC 2-7-1-37 (Protein Kinases) EC 2-7-1 (mTOR protein) Protein Kinases Phosphorylation me [Metabolism] 1-Phosphatidylinositol 3-Kinase Female dt [Drug Therapy] 53123-88-9 (Sirolimus) EC 2-7-1-137 (1-Phosphatidylinositol 3-Kinase) Sirolimus 0 (Chromones) 15663-27-1 (Cisplatin) NIH Research Support-Extramural 0 (Enzyme Inhibitors) Chromones pd [Pharmacology] 70-kDa) EC 2-7-1-37 (Ribosomal Protein S6 Kinases Neoplasm DNA Protein Kinase Inhibitors ae [Adverse Effects] de [Drug Effects] Biological) 0 (Tumor Markers tu [Therapeutic Use] Antineoplastic Combined Chemotherapy Protocols tu [Therapeutic Use] Proportional Hazards Models Enzyme Inhibitors Proto-Oncogene Proteins ai [Antagonists & Inhibitors] EC 3-6-5-2 (ras Proteins) sc [Secondary] 0 (cci 779) Lung Neoplasms Angiomyolipoma Ribosomal Protein S6 Non-US Gov't Support 154447-36-6 (2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one) human) 0 (RHENL1 protein human) 0 (RHEB protein EC 2-7-1-37 (Protein-Serine-Threonine Kinases) an [Analysis] ras Proteins Hematologic Diseases Morpholines Immunoenzyme Techniques Monomeric GTP-Binding Proteins 0 (Morpholines) Interferon-alpha Adult 0 (Proto-Oncogene Proteins) mo [Mortality] Protein-Serine-Threonine Kinases Lymphangioleiomyomatosis Neuropeptides Survival Analysis EC 3-6-5-2 (Monomeric GTP-Binding Proteins) Middle Aged US Gov't Support-PHS Male Cell Division Renal Cell Carcinoma ci [Chemically Induced] Kidney Neoplasms Human EC 2-7-1-37 (proto-oncogene protein akt) Multiple Primary Neoplasms Prognosis Cultured Tumor Cells DNA Mutational Analysis 0 (Interferon-alpha) Antineoplastic Agents Apoptosis Neoplasm) 0 (DNA Ovarian Neoplasms 0 (Neuropeptides) Cisplatin 80 and over Aged Biological Tumor Markers 0 (Ribosomal Protein S6) aa [Analogs & Derivatives] Signal Transduction 70-kDa Ribosomal Protein S6 Kinases Aged 0 (Protein Kinase Inhibitors) 0 (Antineoplastic Agents)
Last updated on Thursday, April 02, 2020